Sage Journals: Discover world-class research

Abstract

Oligoclonal IgM bands (OCMB) against myelin lipids predict an aggressive multiple sclerosis (MS) course. However, the clinical significance of OCMB without lipid specificity, present in other MS patients, remains unknown. We describe here a characterization of these antibodies and study their role in MS progression. Fifty-four MS patients showing CSF-restricted OCMB were included in this study at disease onset and followed-up during 61.1 ± 2.7 months. The specificity of OCMB and the CSF B-cell profile were investigated. A second CSF IgM study was performed in a group of eight patients. Thirty-eight patients showed OCMB against myelin lipids (M+L+) and other sixteen had OCMB lacking this specificity (M+L-). The CD5+ B cell subpopulation, responsible for most persistent IgM responses, was considerably higher in M+L+ than in M+L- patients (3.3 ± 0.6% versus 0.8 ± 0.2, P = 0.009). In addition, M+L+ bands persisted during disease course, while M+L- disappeared during follow-up. M+L+ patients suffered more relapses (4.2 ± 0.6 versus 1.6 ± 0.3, P = 0.002) and reached higher disability (EDSS score of 2.2 ± 0.2 versus 1.2 ± 0.2, P = 0.02) than M+L- group. These data corroborate that anti-lipid OCMB associate with an aggressive MS course and show that OCMB that do not recognize myelin lipids represent a transient immune response related to a more benign disease course. Multiple Sclerosis 2008; 14: 183—187. http://msj.sagepub.com

Keywords

antibodies B lymphocytes IgM multiple sclerosis oligoclonal bands prognosis

Get full access to this article

View all access options for this article.

References

Compston A. , Coles A. Multiple Sclerosis. Lancet 2002; 359: 1221—31.

Ferguson B. , Matyszak MK , Esiri MM , Perry VH Axonal damage in acute multiple sclerosis lesions. Brain 1997; 120: 393—9.

Trapp BD , Peterson J. , Ransohoff RM , Rudick R. , Mork S. , Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278—85.

Lucchinetti C. , Brück W. , Parisi J. , Scheithauer B. , Rodriguez M. , Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47: 707—17.

Bielekova B. , Kadom N. , Fisher E. et al. MRI as a marker for disease heterogeneity in multiple sclerosis. Neurology 2005; 65: 1071—6.

Noseworthy JH , Lucchinetti C. , Rodriguez M. , Weinshenker BG Multiple sclerosis. N Engl J Med 2000; 343: 938—52.

Villar LM , Masjuan J. , González-Porqué P. , Plaza J. , Sádaba MC , Roldán E. et al. Intrathecal IgM synthesis in neurological diseases. Relationship of oligoclonal IgM and disability in MS. Neurology 2002; 58: 824—6.

Villar LM , Plaza J. , Sádaba MC , Roldán E. et al. Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS. Neurology 2002; 59: 555—9.

Villar LM , Masjuan J. , González-Porqué P. , Plaza J. , Sádaba MC , Roldán E. et al. Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis. Ann Neurol 2003; 53: 222—6.

10.

Villar LM , Sádaba MC , Roldán E. , Masjuan J. , González-Porqué P. , Villarrrubia N. et al. Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J Clin Invest 2005; 115: 187—194.

11.

Perini P. , Ranzato F. , Calabrese M. , Battistin L. , Gallo P. Intrathecal IgM production at clinical onset correlates with a more severe disease course in Multiple Sclerosis. J Neurol Neurosurg Psychiatry 2006; 77: 953—5.

12.

McDonald WI , Compston A. , Edan G. , Goodkin D. , Hartung HP , Lublin FD et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121—7.

13.

Poser CM , Paty DW , Scheinberg L. , McDonald WI , Davis FA , Ebers GC et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227—31.

14.

Kurtzke JF Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444—52.

15.

Jacobs LD , Cookfair DL , Rudick RA , Herndon RM , Richert JR , Salazar AM et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis: The multiple sclerosis collaborative research group (MSCRG). Ann Neurol 1996; 39: 285—94.

16.

Arbizu T. , Alvarez-Cermeño JC , Decap G. , Fernandez O. , Uria DF , García-Merino A. et al. Interferon beta-1b treatment in patients with relapsing-remitting multiple sclerosis under a standardized protocol in Spain. Acta Neurol Scand 2000; 102: 209—17.

17.

Sádaba MC , Gonzalez-Porqué P. , Masjuan J. , Álvarez-Cermeño JC , Bootello A. , Villar LM An ultrasensitive method for the detection of oligoclonal IgG bands. J Immunol Meth 2004; 284: 141—5.

18.

Villar LM , Gonzalez-Porqué P. , Masjuan J. , Álvarez-Cermeño JC , Bootello A. , Keir G. A sensitive and reproducible method for the detection of oligoclonal IgM bands . J Immunol Meth 2001; 258: 151—5.

19.

Boes M. Role of natural and immune IgM antibodies in immune responses. Mol Immunol 2000; 37: 1141—9.

20.

Bongioanni P. Lymphocyte subsets in multiple sclerosis. A study with two-colour fluorescence analysis. J Neurol Sci 1996; 139: 71—7.

21.

Cepok S. , Jacobsen M. , Schock S. , Omer B. , Jaekel S. , Boddeker I. et al. Patterns of cerebrospinal fluid pathology correlate with disease progression in multiple sclerosis. Brain 2001 ; 124: 2169—76.

22.

Cepok S. , Rosche B. , Grummel V. , Vogel F. , Zhou D. , Sayn J. et al. Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain 2005 ; 128: 1667—76.

23.

Gay FW , Drye TJ , Dick GW , Esiri M. The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Brain 1997; 120: 1461—83.

24.

Barnett MH , Prineas JW Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesion. Ann Neurol 2004; 55: 458—68.

25.

Genain, CP , Canella B. , Hauser SL , Raine CS Identification of the autoantibodies associated with myelin damage in multiple sclerosis. Nat Med 1999; 5: 153—4.

Influence of oligoclonal IgM specificity in multiple sclerosis disease course

Abstract

Keywords

Get full access to this article

References